David Katz Marker Therapeutics, Inc. Transaction History

Matrix Asset Advisors Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 19, 2023	SELL	$0.24 - $4.58 $36,000 - $687,000	-150,000 Reduced 37.5%	250,000 $0
Q3 2022 Oct 24, 2022	BUY	$0.3 - $3.73 $45,000 - $559,500	150,000 Added 60.0%	400,000 $148,000
Q2 2022 Jul 15, 2022	BUY	$0.26 - $0.46 $26,000 - $46,000	100,000 Added 66.67%	250,000 $83,000
Q4 2021 Feb 10, 2022	BUY	$0.95 - $1.72 $142,500 - $258,000	150,000 New	150,000 $143,000

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $125M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Matrix Asset Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Matrix Asset Advisors Inc and David Katz with notifications on news.